Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPPA
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
BPPA (2,6-bis(3-piperidinopropionamido)anthraquinone) is a small molecule inhibitor of human telomerase reverse transcriptase (hTERT). It specifically targets the catalytic reverse transcriptase domain of telomerase, preventing the maintenance of telomere length and limiting the replicative capacity of highly proliferative cells. BPPA is primarily used as a research-use-only laboratory tool to study telomerase biology, cellular senescence, and host-pathogen interactions, such as the role of host telomerase in the development of Schistosoma mansoni within its snail host Biomphalaria glabrata.
- Other names
- 2,6-bis(3-piperidinopropionamido)anthraquinone2,6-bis(3-piperidinopropionamido)anthraquinone diacetate
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on BPPA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPPA.